Clinical Efficacy Fuzheng Xiao'ai Decoction Treatment for Esophageal Cancer after Chemotherapy
|更新时间:2024-01-04
|
Clinical Efficacy Fuzheng Xiao'ai Decoction Treatment for Esophageal Cancer after Chemotherapy
Chinese Journal of Experimental Traditional Medical FormulaeVol. 18, Issue 20, Pages: 307-309(2012)
作者机构:
作者简介:
基金信息:
DOI:
CLC:
Published:2012
稿件说明:
移动端阅览
DAI Cong-jun, WANG Su. Clinical Efficacy Fuzheng Xiao'ai Decoction Treatment for Esophageal Cancer after Chemotherapy[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(20): 307-309.
DOI:
DAI Cong-jun, WANG Su. Clinical Efficacy Fuzheng Xiao'ai Decoction Treatment for Esophageal Cancer after Chemotherapy[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(20): 307-309.DOI:
Clinical Efficacy Fuzheng Xiao'ai Decoction Treatment for Esophageal Cancer after Chemotherapy
Objective:To observe the clinical efficacy of Fuzheng Xiao'ai decoction (FX) treatment for esophageal cancer after chemotherapy. Method: Seventy-six cases of esophageal cancer after surgery were randomly divided into treatment and control groups. Control group of 37 cases was treated with 5-fluorouracil (5-FU)
cisplatin (DDP)
and with the necessary symptomatic treatment. On the treatment basis of the control group
the treatment group (n=39) was postoperatively started FX for 12 weeks. The adverse reactions
KPS score
and serum immunoglobulin were observed. Result: The incidences of adverse reactions in treatment group were lower than those in the control group (P<0.05
P<0.01) including the delayed gastric emptying
diarrhea
loss of appetite and the weight loss> 5%. After 1 month of treatment
at the end of chemotherapy and two weeks after the end of chemotherapy
KPS score were higher in the treatment group (P<0.01). In the treatment group
IgG
IgA
and IgM levels were higher than those in the controls by the end of the treatment (P<0.05
P<0.01). However
the total effective rates in the treatment group and the control group were 79.48% and 70.27% accordingly. Conclusion: FX can reduce the adverse reactions caused by esophageal cancer surgery and chemotherapy to improve patients' quality of life
Effect of Modified Geqi Powder Combined Concurrent Chemoradiotherapy in Treating 58 Patients with Middle and Terminal Esophageal Cancer
Correlation Between Quality of Life and Traditional Chinese Medicine Syndromes in Patients with Myasthenia Gravis
Baitouweng Tang Inhibits Growth of Esophageal Cancer Cells Through BUB1/STAT3 Signaling Pathway
Chinese Medicine Regulates Signaling Pathways Related to Esophageal Cancer: A Review
Role of NF-κB Signaling Pathway in "Reflux Esophagitis-esophageal Cancer" and Traditional Chinese Medicine Intervention:A Review
Related Author
ZHANG Qiu-feng
LI Ru-hui
JIANG Neng-yi
ZHANG Yibin
LU Qi
WANG Baitong
QI Yixun
XU Hanying
Related Institution
Changchun University of Chinese Medicine
The Third Affiliated Clinical Hospital of Changchun University of Chinese Medicine
The Affiliated Hospital of Changchun University of Chinese Medicine
School of Medicine,Henan University of Chinese Medicine
Henan Key Laboratory of Traditional Chinese Medicine(TCM) Syndrome and Prescription in Signaling, Henan International Joint Laboratory of TCM Syndrome and Prescription in Signaling, TCM School, Henan University of Chinese Medicine